Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: A randomized, single-blind, placebo-controlled, crossover study

Clinical Therapeutics

Volumn 30, Issue 7, 2008, Pages 1283-1289

  Zhang, Wei ^a   Deng, Sheng ^a,b   Chen, Xiao Ping ^a   Zhou, Gan ^a   Xie, Hai Tang ^a   He, Fu Yuan ^a   Cao, Dan ^a   Li, Yuan Jian ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

interaction; rifampicin; rosuvastatin

Indexed keywords

PLACEBO; RIFAMPICIN; ROSUVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTILIPEMIC AGENTS; CROSS-OVER STUDIES; DRUG INTERACTIONS; FLUOROBENZENES; HUMANS; MALE; PYRIMIDINES; RIFAMPIN; SINGLE-BLIND METHOD; SULFONAMIDES;

EID: 48549091752     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(08)80052-5     Document Type: Article

References (34)

1. Davidson M.H. Rosuvastatin: A highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs 11 (2002) 125-141
2. Nezasa K., Higaki K., Takeuchi M., et al. Uptake of rosuvastatin by isolated rat hepatocytes: Comparison with pravastatin. Xenobiotica 33 (2003) 379-388
3. Ho R.H., Tirona R.G., Leake B.F., et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics. Gastroenterology 130 (2006) 1793-1806
4. Martin P.D., Warwick M.J., Dane A.L., et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25 (2003) 2822-2835
5. Schonell M., Dorken E., and Grzybowski S. Rifampin. Can Med Assoc J 106 (1972) 783-786
6. Niemi M., Backman J.T., Fromm M.F., et al. Pharmacokinetic interactions with rifampicin: Clinical relevance. Clin Pharmacokinet 42 (2003) 819-850
7. Chen Y., Ferguson S.S., Negishi M., and Goldstein J.A. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 308 (2004) 495-501
8. Heimark L.D., Gibaldi M., Trager W.F., et al. The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 42 (1987) 388-394
9. Greiner B., Eichelbaum M., Fritz P., et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin [published correction appears in J Clin Invest. 2002;110:571]. J Clin Invest 104 (1999) 147-153
10. Tirona R.G., Leake B.F., Wolkoff A.W., and Kim R.B. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304 (2003) 223-228
11. World Medical Association Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects [WMA Web site]. Ferney-Voltaire, France: WMA; 1989.
12. (April 25, 2007). http://www.wma.net Accessed
13. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6. Geneva, Switzerland: WHO; 2002.
14. (April 25, 2007). http://www.emea.eu.int Accessed
15. Schneck D.W., Birmingham B.K., Zalikowski J.A., et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75 (2004) 455-463
16. Huang X.H., Qiu F.R., Xie H.T., and Li J. Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive dogs. J Cardiovasc Pharmacol 46 (2005) 863-869
17. Xie H.T., Wang G.J., Sun J.G., et al. High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 818 (2005) 167-173
18. Niemi M., Backman J.T., Fromm M.F., et al. Pharmacokinetic interactions with rifampicin: Clinical relevance. Clin Pharmacokinet 42 (2003) 819-850
19. Huang L., Wang Y., and Grimm S. ATP-Dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34 (2006) 738-742
20. Fromm M.F., Kauffmann H.M., Fritz P., et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157 (2000) 1575-1580
21. Kyrklund C., Backman J.T., Kivistö K.T., et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 68 (2000) 592-597
22. Jokubaitis L.A. Updated clinical safety experience with fluvastatin. Am J Cardiol 73 (1994) 18D-24D
23. Backman J.T., Luurila H., Neuvonen M., and Neuvonen P.J. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 78 (2005) 154-167
24. Kyrklund C., Backman J.T., Neuvonen M., and Neuvonen P.J. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol 57 (2004) 181-187
25. Cooper K.J., Martin P.D., Dane A.L., et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 73 (2003) 322-329
26. Cooper K.J., Martin P.D., Dane A.L., et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 58 (2002) 527-531
27. Cooper K.J., Martin P.D., Dane A.L., et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 55 (2003) 94-99
28. Cooper K.J., Martin P.D., Dane A.L., et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 59 (2003) 51-56
29. Carswell C.I., Plosker G.L., and Jarvis B. Rosuvastatin. Drugs 62 (2002) 2075-2085
30. Park J.Y., Kim K.A., Park P.W., et al. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clin Pharmacol Ther 74 (2003) 334-340
31. Vavricka S.R., Van Montfoort J., Ha H.R., et al. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36 (2002) 164-172
32. Jada S.R., Xiaochen S., Yan L.Y., et al. Pharmacogenetics of SLCO1B1: Haplotypes, htSNPs and hepatic expression in three distinct Asian populations [published correction appears in Eur J Clin Pharmacol. 2007;63:813-814]. Eur J Clin Pharmacol 63 (2007) 555-563
33. Floyd M.D., Gervasini G., Masica A.L., et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13 (2003) 595-606
34. Martin P.D., Dane A.L., Nwose O.M., et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: A new HMG-CoA reductase inhibitor. J Clin Pharmacol 42 (2002) 1116-1121